2023 年版WHO基本药物示范目录特点分析及启示
The characteristics and implication of WHO Essential Medicines Model List 2023
韩雨倍 1刘文臣 1陈琛 1杨才君 1方宇1
作者信息
- 1. 西安交通大学药学院 陕西西安 710061;西安交通大学药品安全与政策研究中心 陕西西安 710061
- 折叠
摘要
对2023 年版世界卫生组织的基本药物示范目录(第23 版)与儿童基本药物示范目录(第9 版)进行分析,首先梳理目录调整的工作流程与递交申请所需的材料;接着归纳新版目录的调整依据和特点,目录内的药物数量创历史新高、广泛纳入创新药、审慎遴选儿童药、重视临床获益证据与公共卫生可负担性.建议参考WHO经验,结合国情尽快对我国基本药物目录进行更新,注意基药目录与医保目录的区别与联系,做好目录衔接,满足基本用药需求,确保药品可及性,优化卫生资源配置.
Abstract
The present analysis was based on the iteration of the 2023 WHO Essential Medicines Model List(23rd list)and Essential Medicines Model List for Children(9th list).In a methodological fashion,the adjustment procedure of the basic drug list and the materials required to submit the application were sorted out.Subsequently,a comprehensive synthesis of predominant features characterizing the 2023 edition of the EML and EMLc are summarized(offered).Notably,this edition boasts the highest count of medicines ever included featuring extensive inclusion of innovative drugs to fill the gap,select medicines for children carefully,and the emphasizing on clinical benefit evidence and public health affordability.It is suggested that China should update the NEML according to the national conditions and the experience of WHO as soon as possible,pay attention to the difference and connection between the list of essential medicines and the list of medical insurance,and play a meticulous role for establishing effective linkages between two lists.Such measures are envisaged to meet the basic drug needs,and ensure the accessibility and affordability of drugs,thereby optimizing the allocation of health resources.
关键词
世界卫生组织/基本药物示范目录/遴选程序/循证依据/医保目录Key words
World Health Organization/Essential medicines model list/Selection procedure/Evidence-based reference/Medical insurance drug reimbursement list引用本文复制引用
出版年
2024
NETL
NSTL
万方数据